Get started
DIAMYD MEDICAL AB SER. BDIAMYD MEDICAL AB SER. BDIAMYD MEDICAL AB SER. B

DIAMYD MEDICAL AB SER. B

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

DMYD_B fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen, which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. The company also develops and invests in stem cell and medical technology. Diamyd Medical was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

DMYD_B does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company